Nyhet -

Cancer treatment developed in Sweden may be a game-changer

Cantargia has managed to do what so many other companies in oncology treatment development have failed to do. In just under ten years, Cantargia has been able to advance from an academic environment to a listed company with several ongoing clinical trials. Thus, Cantargia dispels the myth that new treatments in oncology take decades to develop from the initial discovery.

Cantargia’s lead drug nadunolimab has the potential to improve the outcome of standard chemotherapy treatments tremendously and can also help to block further metastatic development. So far, trials of the lead drug involve patients with pancreatic cancer and lung cancer. There are strong indications that nadunolimab may have similar effects on other cancers as well.

May be a game-changer

Things are starting to hype up for Cantargia. During 2021, the well renowned US organization Pancreatic Cancer Action Network, PanCAN, expressed interest in nadunolimab . PanCAN has selected four promising leads to be further developed in collaboration with some of the world’s most prominent hospitals. This is clearly a unique journey very few Biotech founders get the chance to join.

Not only will the PanCAN Precision Promise-based study, where Cantargia’s nadunolimab is included, bring Cantargia into the world’s best environment for developing new treatments for pancreatic cancer. It will also provide substantial funding for taking nadunolimab through a pivotal clinical trial, and a possible commercial launch in around five years’ time.

“Nadunolimab may be a game-changer, and this is what we aim to prove through the study within PanCAN Precision Promise. We are preparing to prove that nadunolimab , used as an add-on to chemotherapy, will indeed increase the life span as well as the quality of life for patients with pancreatic cancer”, says Göran Forsberg, CEO at Cantargia.

Making chemotherapy more targeted

Nadunolimab is designed to primarily attack cancerous cells, leaving healthy cells undamaged. The initial results have so far been very promising, forming the basis for the next step development together with PanCAN.

The importance of the cancer promoting mechanisms counteracted by nadunolimab is becoming increasingly recognised by researchers. Treatments that effectively attack cancerous cells, and can be safely combined with other cancer treatments, are more sought after than ever. Nadunolimab is designed to include both aspects; it blocks the spread of metastases, counteracts resistance against standard chemotherapy in a safe way which is thought to increase life expectancy for cancer patients.

As already mentioned, nadunolimab has the potential to play an important role in several parts of both classical chemotherapy-based drugs but also the novel generation cancer treatment strategies including immune therapy.

“Considering recent advances, it is possible that nadunolimab can be approved as early as 2027, and then with very substantial research and testing behind it. Our main goal is to minimise side effects of traditional cancer treatments and at the same time making them more effective. Considering the current and expected need, what we hope to do is to change the future outcome of cancer treatments”, explains Göran Forsberg.

Cantargia has been granted patents of the target molecule IL1RAP until 2032, and nadunolimab is patented until 2035.



Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterat innehåll

  • Service-oriented mind provides excellent booster for Medicon Valley

    The entrepreneur Ali Ismail is the creator behind three expansive service companies in Lund. Birka BioStorage, Resanitec and Canopus Medical may have different styles, but the common denominator is that they are all service-oriented companies, offering services that complement and make noticeable difference to their customers, especially those located in the Medicon Valley region.
    In 2010, Ali

  • Objective and professional process for a sustainable recruitment

    Agardh Consulting is a recognised partner when it comes to recruitment and HR-related assignments in Lund and Medicon Valley. The company was established six years ago, but founder and owner Pernilla Agardh has over 20 years of experience from the life science industry.
    “I have always maintained a great interest in working with people. Since I have worked in the pharmaceutical industry for so l

  • New precise cancer treatment to be launched during 2022

    Clinical Laserthermia Systems, CLS, is a medical technology company based in Lund that provides precise tools for image-guided laser-mediated thermal ablations. Thermal ablation is used for treatment and removal of diseased or abnormal soft tissues, such as malignant tumours (cancer) or epileptogenic foci.
    Founded in 2006 by Professor Karl-Göran Tranberg, Pär Henriksson and Lars-Erik Eriksson,

  • Rewarding workplace in a vibrant environment

    ProPharma Group is a leading CRO with a global presence across six continents. The office at Medeon Science Park in Malmö was established in 2018 with big plans for growth.
    Now post-pandemic, there are plans to expand ProPharma Group’s presence in Medicon Valley, where ProPharma Group is already a key partner for both large and small life science companies.
    Why Medicon Valley?
    Medicon

  • The best starting point for visiting Medicon Village

    Located at the heart of Lund, close to the botanical gardens, the city centre and the university, Hotel Planetstaden Lund Best Western Plus offers the best starting point for anyone visiting Lund and its vibrant Life science cluster.
    Lund is a very important part of the Medicon Valley region. Being home to Medicon Village, where a lot of companies in Life science thrive, Lund has the potential

  • Get ahead with the right development tools and support from Prevas

    Prevas can take their customers’ projects further than ever before. This is primarily due to dedicated up-scaling of the company’s activities involving Life Science. There is also a brand new strategy in place, clearly defining what the Life Science industry customers need and where Prevas can make a difference.

  • Active Biotech develops first-in-class targets

    Active Biotech is aa company that develops pharmaceutical products within medical areas where the immune defence is significant, including cancer and inflammatory diseases. All of Active Biotech’s leads are first-in-class, unique targets that open completely new opportunities.
    Active Biotech is based in Lund, Sweden, and was formed in 1998 as a spin-off from Pharmacia & Upjohn. Active Biot